Addressing cardiovascular disease in patienths with renal disease

Ethnicity and Disease

Volumn 12, Issue 4, 2002, Pages

  Crook, Errol D ^a   Washington, David O ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Albuminuria; Cardiovascular disease; Hyperlipidemia; Hypertension; Renal disease

Indexed keywords

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW FAT DIET; MORBIDITY; MORTALITY; NUTRITIONAL STATUS; PRACTICE GUIDELINE; PROTEINURIA; REVIEW; RISK FACTOR; SMOKING CESSATION;

ALBUMINURIA; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RISK FACTORS; UNITED STATES;

EID: 0036763328     PISSN: 1049510X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Hall WD. Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci. 1999;317:176-182.
2. Ruilope LM. Kidney dysfunction: a sensitive predictor of cardiovascular risk. Am J Hypertens. 2001;14:213S-217S.
3. Linder A, Charra B, Sherrard DJ, et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701.
4. US Renal Data System. USRDS 1999 Annual Data Report. Bethesda, Md: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1999.
5. Rostand SG, Brunzell JD, Cannon RO, et al. Cardiovascular complications in renal failure. J Am Soc Nephrol. 1991;2:1053-1058.
6. Shemin D, Bostom AG, Laliberty P. et al. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis. 2001;38:85-90.
7. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in the hypertensive subjects of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol. 2001;12:218-225.
8. Mann JFE, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE Randomized Trial. Ann Intern Med. 2001;134:629-636.
9. Fried LP, Kronmal RA, Newman AB, et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA. 1998;279:585-592.
10. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis. 1998;32:853-906.
11. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis. 1998; 32(suppl 3):S5-S13.
12. Crook ED, Flack JM, Salem M, Salahudeen AK, Hall JE. Primary kidney disease as a cardiovascular risk factor. Am J Med Sci. 2002. In press.
13. Pontremoli R, Sofia A, Ravera M, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: a Genoa Investigation on Complications. Hypertension. 1997;30:1135-1143.
14. National Kidney Foundation K/DOQI Working Group. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis. 2002;39(suppl 1):S1-S266.
15. Chertow GM, Normand SL, Silva LR, McNeil BJ. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis [serial online]. 2000;35(6):1044-1051.
16. Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis. 2001;36:820-825.
17. Rostand SG, Kirk KA, Rutsky EA, Pacifico AD. Results of coronary artery bypass grafting in end-stage renal disease. Am J Kidney Dis. 1988;12:266-270.
18. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke. Stroke. 1997;28:557-563.
19. Friedman PJ. Serum creatinine: an independent predictor of survival after stroke. J Intern Med. 1991;229:175-179.
20. Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in Blacks and Whites. Modification of diet in Renal Disease Study Group. Hypertension. 1997;30(3, pt 1):428-435.
21. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998;351:1755-1762.
22. Salem MM. Hypertension in the hemodialysis population: any relationship to 2-years survival? Nephrol Dial Transplant. 1999;14:125-128.
23. Nishizawa Y, Shoji T, Ishimura E, et al. Cardiovascular complications in uremia: paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis. 2001;38(suppl 1):S4-S7.
24. Degoulet P, Legrain M, Reach I, et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane Collaborative Study. Nephron. 1982;31:103-110.
25. Seliger SL, Weiss NS, Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int. 2002;21:297-304.
26. Crook ED. Diabetic renal disease in African Americans. Am J Med Sci. 2002;323:78-84.
27. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and Type 2 diabetes. Diabetes Care. 2000;23(suppl 2):B54-B64.
28. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive Type 2 diabetic patients on albuminuria, retinopathy, and strokes. Kidney Int. 2002;61:1086-1097.
29. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
30. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
31. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
32. Fleishmann E, Teal N, Dudley, et al. Influence of excess weight on mortality and hospital stay in 1,346 hemodialysis patients. Kidney Int. 1999;55:1560-1567.
33. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol. 1997;17:2554-2558.